Preclinical Study Of Adoptive Immunotherapy Against Gastric Cancer Induced By DC

Gastric cancer is one of the most common malignant tumors which are threatening human's health. Current strategies, such as radical operation, chemotherapy, radiotherapy and other synergistic therapies, offer little help to the recovery rate of patients with gastric carcinoma and have only slight impact on their survival, so most patients have to face poor prognosis. A promising approach is immunotherapy based on dendritic cells(DC). DC, one of the most important antigen presenting cells(APC), have been shown strong abilities of antigen capture, process and presentation. Moreover, DC are of the unique capability of inspiring primary immune responses. However, many researches have proved that DC was restrained in a way not only in their number but also in functions underline the tumor microenviroment, thus results in inefficient in uptaking, processing and presenting of antigens and further leads to an anergy in anti-tumor immune responses with lacking of enough activated CTL. Many animal experiments confirmed that a full function of DCs could be recoveried by culturing and maturing in vitro. It has been demonstrated that retransfusion of CTL activated by DC with full function may generate a protective anti-tumor responses, which could efficiently inhibit the tumor growth or destroy them. Recent years, some phase I/II clinical antitumor immunotherapy trials underwent in Europe chief laboratories have shown specific T-cell responses, and partly tumor regressions have been achieved with the use of DCs derived from peripheral blood mononuclear cells(PBMC).Gastric cancer usually mutates on multiple oncogenes with lacking of typical tumor specific antigens. Therapies against a single antigen might be noneffective in the tumor with heterogeneous cell populations and carry the risk of inducing tumor antigen deletion or variants. In addition, this strategy is...